Emerging roles of Toll-like receptor 9 in cardiometabolic disorders

[1]  B. Arneth.  Systemic Lupus Erythematosus and DNA Degradation and Elimination Defects , 2019, Front. Immunol..

[2]  K. Otsu,et al.  Administration of a TLR9 Inhibitor Attenuates the Development and Progression of Heart Failure in Mice , 2019, JACC. Basic to translational science.

[3]  B. Duvvuri,et al.  Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases , 2019, Front. Immunol..

[4]  T. Akasaka,et al.  Toll‐Like Receptor 9 Plays a Pivotal Role in Angiotensin II–Induced Atherosclerosis , 2019, Journal of the American Heart Association.

[5]  Y. Higashikuni,et al.  Activation of Toll-Like Receptor 9 Impairs Blood Flow Recovery After Hind-Limb Ischemia , 2018, Front. Cardiovasc. Med..

[6]  齋藤 義修.  DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway , 2018 .

[7]  D. Cram,et al.  High levels of circulating cell‐free DNA are a biomarker of active SLE , 2018, European journal of clinical investigation.

[8]  T. Kodama,et al.  DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway , 2018, Cell Death & Differentiation.

[9]  S. Grazioli,et al.  Mitochondrial Damage-Associated Molecular Patterns: From Inflammatory Signaling to Human Diseases , 2018, Front. Immunol..

[10]  J. Lyu,et al.  Plasma‐derived exosomes contribute to inflammation via the TLR9‐NF‐&kgr;B pathway in chronic heart failure patients , 2017, Molecular immunology.

[11]  L. Bryzgalov,et al.  Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers , 2017, Arthritis Research & Therapy.

[12]  L. Pączek,et al.  The role and diagnostic value of cell-free DNA in systemic lupus erythematosus. , 2017, Clinical and experimental rheumatology.

[13]  R. Arbeit,et al.  IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. , 2017, Clinical immunology.

[14]  A. Engin.  Adipocyte-Macrophage Cross-Talk in Obesity. , 2017, Advances in experimental medicine and biology.

[15]  S. Alavian,et al.  Liver Mitochondrial DNA Copy Number and Deletion Levels May Contribute to Nonalcoholic Fatty Liver Disease Susceptibility , 2016, Hepatitis monthly.

[16]  N. Pace,et al.  The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis , 2016, International journal of inflammation.

[17]  C. Liu,et al.  Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. , 2016, Cell reports.

[18]  I. Seljeflot,et al.  Extracellular mtDNA activates NF-κB via toll-like receptor 9 and induces cell death in cardiomyocytes , 2016, Basic Research in Cardiology.

[19]  I. Imoto,et al.  Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance , 2016, Science Advances.

[20]  R. Coffman,et al.  Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. , 2016, The Journal of clinical investigation.

[21]  S. Zimmer,et al.  Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice , 2016, PloS one.

[22]  You-Me Kim,et al.  TLR9 regulates adipose tissue inflammation and obesity‐related metabolic disorders , 2015, Obesity.

[23]  M. Clément,et al.  CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. , 2015, Journal of autoimmunity.

[24]  Ling Lin,et al.  Toll-Like Receptor 9 Inactivation Alleviated Atherosclerotic Progression and Inhibited Macrophage Polarized to M1 Phenotype in ApoE−/− Mice , 2015, Disease markers.

[25]  T. Gould,et al.  Extracellular DNA and histones: double‐edged swords in immunothrombosis , 2015, Journal of thrombosis and haemostasis : JTH.

[26]  S. Subramanian,et al.  Anti-HMGB1 antibody reduces weight gain in mice fed a high-fat diet , 2015, Nutrition & Diabetes.

[27]  L. Velloso,et al.  TLR4 at the Crossroads of Nutrients, Gut Microbiota, and Metabolic Inflammation. , 2015, Endocrine reviews.

[28]  Daniel Konrad,et al.  The gut-adipose-liver axis in the metabolic syndrome. , 2014, Physiology.

[29]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[30]  F. Perez-Vizcaino,et al.  Chronic Hydroxychloroquine Improves Endothelial Dysfunction and Protects Kidney in a Mouse Model of Systemic Lupus Erythematosus , 2014, Hypertension.

[31]  A. Dick,et al.  TLR9 agonist regulates angiogenesis and inhibits corneal neovascularization. , 2014, The American journal of pathology.

[32]  J. Kalbfleisch,et al.  The TLR9 Ligand, CpG‐ODN, Induces Protection against Cerebral Ischemia/Reperfusion Injury via Activation of PI3K/Akt Signaling , 2014, Journal of the American Heart Association.

[33]  S. Akira,et al.  Protective Role for Toll-Like Receptor-9 in the Development of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[34]  F. Villarroya,et al.  Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells , 2014, International Journal of Obesity.

[35]  Guochun Wang,et al.  Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. , 2014, Internal medicine.

[36]  Y. Higashikuni,et al.  HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9. , 2013, Atherosclerosis.

[37]  K. Otsu,et al.  Translation of hemodynamic stress to sterile inflammation in the heart , 2013, Trends in Endocrinology & Metabolism.

[38]  J. Rutledge,et al.  Inflammasome-Mediated Secretion of IL-1β in Human Monocytes through TLR2 Activation; Modulation by Dietary Fatty Acids , 2013, The Journal of Immunology.

[39]  T. Zuo,et al.  Chloroquine pretreatment inhibits toll-like receptor 3 signaling after stroke , 2013, Neuroscience Letters.

[40]  H. Crijns,et al.  Elevated Levels of Circulating DNA and Chromatin Are Independently Associated With Severe Coronary Atherosclerosis and a Prothrombotic State , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[41]  R. Flavell,et al.  Innate sensors of pathogen and stress: linking inflammation to obesity. , 2013, The Journal of allergy and clinical immunology.

[42]  C. Monaco,et al.  Toll-Like Receptors in Atherosclerosis , 2013, International journal of molecular sciences.

[43]  A. Bowie,et al.  Immune sensing of DNA. , 2013, Immunity.

[44]  T. Pawson,et al.  Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. , 2013, Cell metabolism.

[45]  A. Bennakhi,et al.  Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation , 2012, Journal of Inflammation.

[46]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[47]  J. Hamming,et al.  Blocking Toll-Like Receptors 7 and 9 Reduces Postinterventional Remodeling via Reduced Macrophage Activation, Foam Cell Formation, and Migration , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[48]  S. Akira,et al.  Mitochondrial DNA That Escapes from Autophagy Causes Inflammation and Heart Failure , 2012, Nature.

[49]  A. Fairhurst,et al.  TLR7 and TLR9 in SLE: when sensing self goes wrong , 2012, Immunologic research.

[50]  G. Shulman,et al.  Mechanisms for Insulin Resistance: Common Threads and Missing Links , 2012, Cell.

[51]  T. Weichhart,et al.  Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  S. Devaraj,et al.  Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome , 2012, Diabetes Care.

[53]  Seung‐Jin Kim,et al.  Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. , 2012, The Journal of nutritional biochemistry.

[54]  Yue Zheng,et al.  Damage-Associated Molecular Patterns , and Sterile Inflammation in Cardiovascular Disease , 2011 .

[55]  J. Bargman,et al.  The role of antimalarial agents in the treatment of SLE and lupus nephritis , 2011, Nature Reviews Nephrology.

[56]  P. Doevendans,et al.  Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis. , 2011, Clinical science.

[57]  P. Sansonetti,et al.  Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment , 2011, EMBO molecular medicine.

[58]  M. Fresno,et al.  Toll-like receptors, inflammation, metabolism and obesity , 2011, Archives of physiology and biochemistry.

[59]  D. Schrijvers,et al.  Necrotic cell death in atherosclerosis , 2011, Basic Research in Cardiology.

[60]  U. Švajger,et al.  Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines , 2011, The Journal of Immunology.

[61]  S. Tangye,et al.  Inflammatory Mechanisms in Obesity , 2013 .

[62]  Chad A. Cowan,et al.  Rapid Cellular Turnover in Adipose Tissue , 2011, PloS one.

[63]  Jeremy E. Davis,et al.  Absence of Tlr2 protects against high-fat diet-induced inflammation and results in greater insulin-stimulated glucose transport in cultured adipocytes. , 2011, The Journal of nutritional biochemistry.

[64]  K. Peter,et al.  High-Mobility Group Box Protein 1 Neutralization Reduces Development of Diet-Induced Atherosclerosis in Apolipoprotein E–Deficient Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[65]  A. C. Könner,et al.  Toll-like receptors: linking inflammation to metabolism , 2011, Trends in Endocrinology & Metabolism.

[66]  N. Tsuchimori,et al.  TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules , 2011, Molecular Pharmacology.

[67]  M. Bagot,et al.  IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro , 2010, European journal of immunology.

[68]  Jon Cohen,et al.  A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis* , 2010, Critical care medicine.

[69]  T. Suganami,et al.  Adipose tissue macrophages: their role in adipose tissue remodeling , 2010, Journal of leukocyte biology.

[70]  D. Brenner,et al.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. , 2010, Gastroenterology.

[71]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[72]  R. Sorrentino,et al.  The activation of liver X receptors inhibits toll‐like receptor‐9‐induced foam cell formation , 2010, Journal of cellular physiology.

[73]  P. J. Pretorius,et al.  Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? , 2010, Clinical biochemistry.

[74]  J. Tanus-Santos,et al.  Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[75]  S. Bombardieri,et al.  Cell-free DNA in the plasma of patients with systemic sclerosis , 2009, Clinical Rheumatology.

[76]  S. Schinner,et al.  Adipocyte Death, Adipose Tissue Remodeling, and Obesity Complications , 2009 .

[77]  S. Baek,et al.  A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. , 2008, Cellular signalling.

[78]  G. Hotamisligil,et al.  Nutrient sensing and inflammation in metabolic diseases , 2008, Nature Reviews Immunology.

[79]  S. Akira,et al.  Excessive CpG 1668 stimulation triggers IL‐10 production by cDC that inhibits IFN‐α responses by pDC , 2008, European journal of immunology.

[80]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[81]  T. Kaisho,et al.  Turning NF-kappaB and IRFs on and off in DC. , 2008, Trends in immunology.

[82]  E. Ruokonen,et al.  Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. , 2008, Clinical chemistry.

[83]  R. Coffman,et al.  Treatment of lupus‐prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms , 2007, European journal of immunology.

[84]  K. Strissel,et al.  Adipocyte Death, Adipose Tissue Remodeling, and Obesity Complications , 2007, Diabetes.

[85]  G. Ertl,et al.  Mechanisms of Disease: Toll-like receptors in cardiovascular disease , 2007, Nature Clinical Practice Cardiovascular Medicine.

[86]  S. Baek,et al.  Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression , 2007, Experimental & Molecular Medicine.

[87]  Vishnu Swarup,et al.  Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases , 2007, FEBS letters.

[88]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[89]  E. Chaikof,et al.  Pathogen-Sensing Plasmacytoid Dendritic Cells Stimulate Cytotoxic T-Cell Function in the Atherosclerotic Plaque Through Interferon-&agr; , 2006, Circulation.

[90]  K. Walley,et al.  Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. , 2006, Cardiovascular research.

[91]  A. Marshak‐Rothstein.  Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.

[92]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[93]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[94]  T. Suganami,et al.  A Paracrine Loop Between Adipocytes and Macrophages Aggravates Inflammatory Changes: Role of Free Fatty Acids and Tumor Necrosis Factor α , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[95]  Shizuo Akira,et al.  Shared and Unique Functions of the DExD/H-Box Helicases RIG-I, MDA5, and LGP2 in Antiviral Innate Immunity1 , 2005, The Journal of Immunology.

[96]  P. Iyengar,et al.  Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy , 2005, Nature Medicine.

[97]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[98]  Shizuo Akira,et al.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.

[99]  B. Monks,et al.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome , 2004, Nature Immunology.

[100]  T. Littlewood,et al.  Apoptotic cell death in atherosclerosis , 2003, Current Opinion in Lipidology.

[101]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[102]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[103]  G. Hansson,et al.  Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation , 2002, Circulation.

[104]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.

[105]  M. Fishbein,et al.  Toll-Like Receptor-4 Is Expressed by Macrophages in Murine and Human Lipid-Rich Atherosclerotic Plaques and Upregulated by Oxidized LDL , 2001, Circulation.

[106]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[107]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[108]  J. Isner,et al.  Apoptosis in human atherosclerosis and restenosis. , 1995, Circulation.

[109]  D. A. Clayton,et al.  Pervasive CpG suppression in animal mitochondrial genomes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[110]  M. Szyf,et al.  Methylation pattern of mouse mitochondrial DNA. , 1984, Nucleic acids research.

[111]  P. Schur,et al.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. , 1966, The Journal of clinical investigation.